IL133032A - Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells - Google Patents

Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells

Info

Publication number: IL133032A
Authority: IL; Israel
Prior art keywords: adenovirus; cells; fiber; cell; virus
Prior art date: 1998-11-20

Application number

IL133032A

Other languages

English (en)

Other versions

IL133032A0 (en

Original Assignee

Introgene Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-20

Filing date

1999-11-18

Publication date

2007-06-03

1999-11-18 Application filed by Introgene Bv filed Critical Introgene Bv

2001-03-19 Publication of IL133032A0 publication Critical patent/IL133032A0/xx

2007-06-03 Publication of IL133032A publication Critical patent/IL133032A/en

Links

210000000329 smooth muscle myocyte Anatomy 0.000 title abstract description 41
230000005100 tissue tropism Effects 0.000 title abstract description 37
210000002889 endothelial cell Anatomy 0.000 title abstract description 36
239000013598 vector Substances 0.000 title description 107
238000001476 gene delivery Methods 0.000 title description 26
241000701161 unidentified adenovirus Species 0.000 abstract description 281
241000700605 Viruses Species 0.000 abstract description 123
150000007523 nucleic acids Chemical class 0.000 abstract description 45
102000039446 nucleic acids Human genes 0.000 abstract description 43
108020004707 nucleic acids Proteins 0.000 abstract description 43
210000000234 capsid Anatomy 0.000 abstract description 39
238000000034 method Methods 0.000 abstract description 19
238000012384 transportation and delivery Methods 0.000 abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
108700026758 Adenovirus hexon capsid Proteins 0.000 abstract description 8
201000010099 disease Diseases 0.000 abstract description 8
208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
210000004027 cell Anatomy 0.000 description 224
108090000623 proteins and genes Proteins 0.000 description 152
239000000835 fiber Substances 0.000 description 110
102000004169 proteins and genes Human genes 0.000 description 70
235000018102 proteins Nutrition 0.000 description 66
241001135569 Human adenovirus 5 Species 0.000 description 63
101710145505 Fiber protein Proteins 0.000 description 61
239000012634 fragment Substances 0.000 description 51
208000015181 infectious disease Diseases 0.000 description 51
230000014509 gene expression Effects 0.000 description 30
108020004414 DNA Proteins 0.000 description 22
238000002474 experimental method Methods 0.000 description 22
102000005962 receptors Human genes 0.000 description 22
108020003175 receptors Proteins 0.000 description 22
230000027455 binding Effects 0.000 description 21
239000002245 particle Substances 0.000 description 21
239000003981 vehicle Substances 0.000 description 21
238000001415 gene therapy Methods 0.000 description 20
238000004806 packaging method and process Methods 0.000 description 20
210000004185 liver Anatomy 0.000 description 19
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 18
108060001084 Luciferase Proteins 0.000 description 18
239000005089 Luciferase Substances 0.000 description 18
108700019146 Transgenes Proteins 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
108090000565 Capsid Proteins Proteins 0.000 description 16
102100023321 Ceruloplasmin Human genes 0.000 description 16
230000001413 cellular effect Effects 0.000 description 15
210000005229 liver cell Anatomy 0.000 description 15
230000000694 effects Effects 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
239000002609 medium Substances 0.000 description 14
230000010076 replication Effects 0.000 description 14
230000037431 insertion Effects 0.000 description 13
238000003780 insertion Methods 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
102000006495 integrins Human genes 0.000 description 12
108010044426 integrins Proteins 0.000 description 12
238000012546 transfer Methods 0.000 description 12
108091034117 Oligonucleotide Proteins 0.000 description 11
241000700159 Rattus Species 0.000 description 11
230000006870 function Effects 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
102100021242 Dymeclin Human genes 0.000 description 10
101000817629 Homo sapiens Dymeclin Proteins 0.000 description 10
238000010361 transduction Methods 0.000 description 10
230000026683 transduction Effects 0.000 description 10
108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 9
230000037430 deletion Effects 0.000 description 9
238000012217 deletion Methods 0.000 description 9
239000005090 green fluorescent protein Substances 0.000 description 9
210000000056 organ Anatomy 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
230000010415 tropism Effects 0.000 description 8
210000003462 vein Anatomy 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000003321 amplification Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
230000028993 immune response Effects 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
208000037803 restenosis Diseases 0.000 description 6
238000010186 staining Methods 0.000 description 6
239000013603 viral vector Substances 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
210000004351 coronary vessel Anatomy 0.000 description 5
238000000502 dialysis Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000003752 saphenous vein Anatomy 0.000 description 5
210000003606 umbilical vein Anatomy 0.000 description 5
101150076401 16 gene Proteins 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000701109 Human adenovirus 2 Species 0.000 description 4
241000598171 Human adenovirus sp. Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
210000000612 antigen-presenting cell Anatomy 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000012139 lysis buffer Substances 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000008685 targeting Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
101710094648 Coat protein Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
101710125418 Major capsid protein Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
101710141454 Nucleoprotein Proteins 0.000 description 3
101710083689 Probable capsid protein Proteins 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
230000004075 alteration Effects 0.000 description 3
238000004873 anchoring Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000007887 coronary angioplasty Methods 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
102000043827 human Smooth muscle Human genes 0.000 description 3
108700038605 human Smooth muscle Proteins 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
241000709687 Coxsackievirus Species 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241001428587 Human adenovirus 16 Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
108010084938 adenovirus receptor Proteins 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000037029 cross reaction Effects 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003531 protein hydrolysate Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
201000011244 Acrocallosal syndrome Diseases 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
201000000054 Coronary Restenosis Diseases 0.000 description 1
206010056489 Coronary artery restenosis Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
101150066038 E4 gene Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101710094396 Hexon protein Proteins 0.000 description 1
101710155188 Hexon-interlacing protein Proteins 0.000 description 1
241000701190 Human adenovirus 11 Species 0.000 description 1
241001135567 Human adenovirus 40 Species 0.000 description 1
241000701096 Human adenovirus 7 Species 0.000 description 1
241000193096 Human adenovirus B3 Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108091036060 Linker DNA Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
101710173835 Penton protein Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000005228 Pericardial Effusion Diseases 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
101710164463 Preterminal protein Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000567363 Puccinellia maritima Species 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
241001068263 Replication competent viruses Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
108700025771 adenovirus penton Proteins 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000011143 downstream manufacturing Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000008497 endothelial barrier function Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
210000005033 mesothelial cell Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004912 pericardial fluid Anatomy 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
239000013589 supplement Substances 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL133032A 1998-11-20 1999-11-18 Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells IL133032A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98203921		1998-11-20

Publications (2)

Publication Number	Publication Date
IL133032A0 IL133032A0 (en)	2001-03-19
IL133032A true IL133032A (en)	2007-06-03

Family

ID=8234363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL133032A IL133032A (en)	1998-11-20	1999-11-18	Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells

Country Status (12)

Country	Link
JP (1)	JP4683682B2 (de)
AT (1)	ATE296894T1 (de)
AU (1)	AU770780B2 (de)
CA (1)	CA2318492C (de)
DE (1)	DE69925567T2 (de)
ES (1)	ES2244145T3 (de)
IL (1)	IL133032A (de)
MX (1)	MXPA99010682A (de)
NO (1)	NO995697L (de)
NZ (1)	NZ501214A (de)
WO (1)	WO2000031285A1 (de)
ZA (1)	ZA997213B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
ATE403006T1 (de) *	1999-03-04	2008-08-15	Crucell Holland Bv	Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
CA2410665C (en)	2000-05-31	2017-11-07	University Of Saskatchewan	Modified bovine adenovirus having altered tropism
EP1322774A2 (de) *	2000-09-20	2003-07-02	Crucell Holland B.V.	Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
DE60138403D1 (de)	2000-09-26	2009-05-28	Crucell Holland Bv	Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US6905678B2 (en) *	2001-07-07	2005-06-14	Crucell Holland B.V.	Gene delivery vectors with cell type specificity for mesenchymal stem cells
PL215165B1 (pl)	2002-04-25	2013-10-31	Crucell Holland Bv	Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
EP1482052A1 (de) *	2003-05-27	2004-12-01	Cytos Biotechnology AG	Modifizierte Polypeptide zur Zielrichtung des Zelleintritts von Subtyp B Adenoviren
KR102702230B1 (ko)	2017-05-26	2024-09-03	에피센트알엑스, 인코포레이티드	트랜스진을 보유하는 재조합 아데노바이러스

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5770442A (en) *	1995-02-21	1998-06-23	Cornell Research Foundation, Inc.	Chimeric adenoviral fiber protein and methods of using same
KR100470180B1 (ko) *	1995-06-15	2005-02-04	크루셀 홀란드 비.브이.	유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
JP3420586B2 (ja) *	1995-11-28	2003-06-23	ジェンベク、インコーポレイティッド	細胞への遣伝子導入のためのベクターおよび方法
US5877011A (en) *	1996-11-20	1999-03-02	Genzyme Corporation	Chimeric adenoviral vectors
FR2758822B1 (fr) *	1997-01-30	1999-07-02	Centre Nat Rech Scient	Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus
FR2761689B1 (fr) *	1997-04-02	1999-06-25	Transgene Sa	Fibre adenovirale modifiee et adenovirus cibles

1999
- 1999-11-18 IL IL133032A patent/IL133032A/en not_active IP Right Cessation
- 1999-11-19 DE DE69925567T patent/DE69925567T2/de not_active Expired - Lifetime
- 1999-11-19 ES ES99203878T patent/ES2244145T3/es not_active Expired - Lifetime
- 1999-11-19 AT AT99203878T patent/ATE296894T1/de not_active IP Right Cessation
- 1999-11-19 ZA ZA9907213A patent/ZA997213B/xx unknown
- 1999-11-19 NO NO995697A patent/NO995697L/no not_active Application Discontinuation
- 1999-11-19 MX MXPA99010682A patent/MXPA99010682A/es not_active IP Right Cessation
- 1999-11-22 NZ NZ501214A patent/NZ501214A/en not_active IP Right Cessation
- 1999-11-22 JP JP33203399A patent/JP4683682B2/ja not_active Expired - Fee Related
- 1999-11-22 CA CA2318492A patent/CA2318492C/en not_active Expired - Fee Related
- 1999-11-22 WO PCT/NL1999/000717 patent/WO2000031285A1/en not_active Ceased
- 1999-11-22 AU AU59600/99A patent/AU770780B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP4683682B2 (ja)	2011-05-18
DE69925567D1 (de)	2005-07-07
NO995697L (no)	2000-05-22
ATE296894T1 (de)	2005-06-15
DE69925567T2 (de)	2006-05-04
ZA997213B (en)	2000-05-22
ES2244145T3 (es)	2005-12-01
CA2318492A1 (en)	2000-06-02
CA2318492C (en)	2010-05-11
MXPA99010682A (es)	2002-03-08
AU770780B2 (en)	2004-03-04
AU5960099A (en)	2000-05-25
IL133032A0 (en)	2001-03-19
WO2000031285A1 (en)	2000-06-02
NO995697D0 (no)	1999-11-19
JP2000157289A (ja)	2000-06-13
NZ501214A (en)	2002-02-01

Legal Events

Date	Code	Title
2007-10-31	FF	Patent granted
2008-01-06	KB	Patent renewed
2013-11-28	KB	Patent renewed
2018-06-28	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US7968087B2 (en)	2011-06-28	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6803234B2 (en)	2004-10-12	Gene delivery vectors with cell type specificity for primary human chondrocytes
JP4472178B2 (ja)	2010-06-02	キメラアデノウイルス
CA2364499C (en)	2008-12-23	Means and methods for fibroblast-like or macrophage-like cell transduction
AU2002315947B2 (en)	2007-09-06	Adenoviral vectors with cell type specificity for mesenchymal cells
AU2002315947A1 (en)	2003-05-22	Adenoviral vectors with cell type specificity for mesenchymal cells
Denby et al.	2004	Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo
US7238528B2 (en)	2007-07-03	Means and methods for fibroblast-like or macrophage-like cell transduction
AU770780B2 (en)	2004-03-04	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1020529B1 (de)	2005-06-01	Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
EP1191104A1 (de)	2002-03-27	Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen
EP1191105A1 (de)	2002-03-27	Gentransfervektoren mit einer Gewebsspezifität für T-Lymphozyten
AU2001294348B2 (en)	2007-04-19	Transduction of chondrocytes using adenoviral vectors
EP1195440A1 (de)	2002-04-10	Genverabreichung-Vektoren für Stammzellen
NZ527634A (en)	2004-03-26	Means and methods for synoviocyte cell transduction
AU2001294348A1 (en)	2002-05-16	Transduction of chondrocytes using adenoviral vectors